Jamie Clark

Is the FDA stubbing out tobacco stocks?

Jamie Clark

At the end of July the tobacco industry was dealt another blow, this time by the US Food and Drug Administration, which committed to cutting nicotine levels in a bid to reduce addiction to cigarettes. This intervention reinforces why we have long-avoided tobacco stocks within our Macro Equity Income and Macro UK Growth funds.

Since November 2012, against a backdrop of increased smoking restrictions in emerging markets and cigarette branding bans coming into force, we have employed an Avoiding Tobacco theme. We saw the emergence of an attitude shift, which, we felt, may eventually lead to the sector finally being consigned to the ex-growth bucket.

The FDA was first given powerful tools to reduce the harm caused by tobacco when the Family Smoking Prevention and Tobacco Control act was passed in 2009, and finally it seems they might use them, with the body’s Center for Tobacco Products now working on a regulatory plan to confront cigarette addiction. On the day of the FDA’s July announcement, tobacco stocks from both sides of the Atlantic encountered a sell-off, with British American Tobacco shares falling c.7% and Altria Group down nearly 10%. They have yet to recover.

The touchstone for tobacco regulation – the World Health Organization Framework Convention on Tobacco Control (WHO FCTC) – has been in force since 2005 - 180 countries are signatories and it’s legally binding in 168 countries - and we expect regulation to continue choking tobacco companies’ profits. Developing markets have already followed the lead of developed markets in legislating to curtail the industry’s activities and contain its manifold economic externalities, which include escalating healthcare costs.  

Furthermore, we remain sceptical about the ability of next generation tobacco products, such as vaping, to replace smokers. We believe that the barriers to entry in this market are limited, so incumbent players are not only competing with each other, but new players too.

So as the FDA wages war on addiction to cigarettes, where else might investors look? We believe the telecoms is well positioned to take the reins from tobacco as the foremost ‘addiction’ income play, given consumers’ dependence on data consumption. In our Global Telecoms theme, we take the view that a content-led offering will be key in enabling operators to leverage unprecedented rates of data consumption and convert it to top line growth.


• This content contains information and analysis that is believed to be accurate at the date of publication but is subject to change without notice. Whilst care has been taken in compiling this content, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness. Some parts/sections of this content may been compiled from external sources. Whilst these sources are believed to be reliable, the information has not been independently verified and therefore no representation is made as to its accuracy or completeness. • It should not be copied, faxed, reproduced, divulged or distributed, in whole or in part, without the express written consent of Liontrust. • Past performance is not a guide to future performance. Do remember that the value of an investment and the income generated from them can fall as well as rise and is not guaranteed, therefore, you may not get back the amount originally invested and potentially risk total loss of capital. The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term. • Any decision to invest should be always based on the final Prospectus and Key Investor Information Documents (KIIDs) and you should take independent legal advice if necessary. These documents contain important information which should be read before investing in any fund and they can be obtained, free of charge, here.

• Investment in Funds managed by the Macro Thematic team involves foreign currencies and may be subject to fluctuations in value due to movements in exchange rates. The Funds' expenses are charged to capital. This has the effect of increasing dividends while constraining capital appreciation. The performance of the Liontrust GF Macro Equity Income Fund may differ from the performance of the Liontrust Macro Equity Income Fund and is likely to be lower than its corresponding Master Fund due to additional fees and expenses.

Thursday, August 3, 2017, 9:40 AM